KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Receivables - Other (2016)

Historic Receivables - Other for Biomarin Pharmaceutical (BMRN) over the last 5 years, with Q3 2016 value amounting to $8.4 million.

  • Biomarin Pharmaceutical's Receivables - Other changed N/A to $8.4 million in Q3 2016 from the same period last year, while for Sep 2016 it was $8.4 million, marking a year-over-year change of. This contributed to the annual value of $116.5 million for FY2013, which is N/A changed from last year.
  • According to the latest figures from Q3 2016, Biomarin Pharmaceutical's Receivables - Other is $8.4 million.
  • In the past 5 years, Biomarin Pharmaceutical's Receivables - Other registered a high of $116.5 million during Q4 2013, and its lowest value of $6.8 million during Q1 2012.
  • In the last 3 years, Biomarin Pharmaceutical's Receivables - Other had a median value of $9.0 million in 2012 and averaged $30.1 million.
  • Over the last 5 years, Biomarin Pharmaceutical's Receivables - Other had its largest YoY gain of 11189.86% in 2012, and its largest YoY loss of 2380.56% in 2012.
  • Over the past 3 years, Biomarin Pharmaceutical's Receivables - Other (Quarter) stood at $9.0 million in 2012, then soared by 1191.86% to $116.5 million in 2013, then crashed by 92.79% to $8.4 million in 2016.
  • Its Receivables - Other stands at $8.4 million for Q3 2016, versus $116.5 million for Q4 2013 and $9.0 million for Q3 2012.